Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $305.93, for a total value of $305,930.00. Following the completion of the transaction, the director now directly owns 11,323 shares in the company, valued at $3,464,045.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Shares of NASDAQ REGN traded up $3.43 during midday trading on Thursday, reaching $308.05. 704,583 shares of the company’s stock were exchanged, compared to its average volume of 782,783. Regeneron Pharmaceuticals Inc has a 52-week low of $291.10 and a 52-week high of $442.00. The firm has a market cap of $33.82 billion, a price-to-earnings ratio of 15.56, a PEG ratio of 1.44 and a beta of 1.08. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.78 and a current ratio of 4.58.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $4.45 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $5.24 by ($0.79). Regeneron Pharmaceuticals had a return on equity of 26.95% and a net margin of 35.13%. The business had revenue of $1.71 billion for the quarter, compared to analysts’ expectations of $1.76 billion. During the same period in the previous year, the firm posted $4.67 earnings per share. The firm’s revenue was up 13.3% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals Inc will post 18.37 EPS for the current year.
Several research analysts have commented on the company. ValuEngine lowered Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday. Cantor Fitzgerald cut their price objective on Regeneron Pharmaceuticals from $441.00 to $405.00 and set a “neutral” rating on the stock in a research report on Monday. BMO Capital Markets cut their price objective on Regeneron Pharmaceuticals from $412.00 to $375.00 and set a “market perform” rating on the stock in a research report on Wednesday, May 8th. Morgan Stanley cut their price objective on Regeneron Pharmaceuticals from $420.00 to $389.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 8th. Finally, Canaccord Genuity reissued a “hold” rating and issued a $353.00 price objective (down from $408.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, May 8th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $404.88.
Several hedge funds and other institutional investors have recently made changes to their positions in REGN. BlackRock Inc. increased its holdings in Regeneron Pharmaceuticals by 1.9% in the first quarter. BlackRock Inc. now owns 6,042,908 shares of the biopharmaceutical company’s stock valued at $2,481,339,000 after buying an additional 113,683 shares during the last quarter. Vanguard Group Inc increased its holdings in Regeneron Pharmaceuticals by 1.3% in the third quarter. Vanguard Group Inc now owns 5,754,927 shares of the biopharmaceutical company’s stock valued at $2,325,220,000 after buying an additional 75,868 shares during the last quarter. FMR LLC increased its holdings in Regeneron Pharmaceuticals by 6.6% in the fourth quarter. FMR LLC now owns 5,347,376 shares of the biopharmaceutical company’s stock valued at $1,997,245,000 after buying an additional 330,875 shares during the last quarter. Loomis Sayles & Co. L P increased its holdings in Regeneron Pharmaceuticals by 0.5% in the first quarter. Loomis Sayles & Co. L P now owns 3,176,687 shares of the biopharmaceutical company’s stock valued at $1,304,411,000 after buying an additional 15,540 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Regeneron Pharmaceuticals by 1.8% in the first quarter. Geode Capital Management LLC now owns 1,097,848 shares of the biopharmaceutical company’s stock valued at $450,007,000 after buying an additional 19,395 shares during the last quarter. 67.63% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This report was first posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://transcriptdaily.com/2019/05/16/regeneron-pharmaceuticals-inc-regn-director-joseph-l-goldstein-sells-1000-shares.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Recommended Story: What do investors mean by earnings per share?
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.